Basic fibroblast growth factor treatment for skin ulcerations in scleroderma.
We report the use of topical application of recombinant human basic fibroblast growth factor (rhbFGF) to successfully treat therapy-resistant, chronic leg ulcers in scleroderma. Endothelial cell FGF receptors are directly stimulated by bFGF; also, bFGF promotes the regeneration of capillary-rich granulation tissue. We conclude that topical bFGF may be a powerful new pharmacologic tool for treating severe skin ulcers.
Yamanaka
Kei-ichi
K
Department of Dermatology, Mie University, Graduate School of Medicine, Japan. yamake@clin.medic.mie-u.ac.jp
Inaba
Tomoko
T
Nomura
Eriko
E
Hurwitz
Daniel
D
Jones
David A
DA
Hakamada
Arata
A
Isoda
Kenichi
K
Kupper
Thomas S
TS
Mizutani
Hitoshi
H
D000279:Administration, Cutaneous; D000527:Alprostadil / Q000627:therapeutic use; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D006801:Humans; D007871:Leg Ulcer / Q000188:drug therapy* / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D008875:Middle Aged; D017285:Polymyositis / Q000150:complications; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012595:Scleroderma, Systemic / Q000150:complications*; D014665:Vasodilator Agents / Q000627:therapeutic use
C100666:KCB-1 protein, recombinant; D011994:Recombinant Proteins; D014665:Vasodilator Agents; D016222:Fibroblast Growth Factor 2; D000527:Alprostadil